Current FDA approval of this adaptive system is for the treatment of Parkinson’s only, not essential tremor, dystonia (a ...

There is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain stimulator that could benefit patients with the motor condition.

Getting a headache and feeling sick are common side-effects for many medicines. Indulging in risky sexual behavior or ...

Opens in a new tab or window The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode identifier) for people with Parkinson's disease ...

Deep brain stimulation (DBS) is often used in refractory cases of Parkinson’s disease as well as in a number of other movement disorders. Electrodes are placed in deep nuclei of the brain ...

Parkinson’s disease is a degenerative brain condition that tends to affect motor functions. The most visible signs include balance problems, tremors, rigidity and slowness. The disease affects ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease. The FDA approved adaptive deep brain stimulation (aDBS ...

The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s disease. The new technology is expected to be available in the US later in 2025.

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation approach ...